Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Conditions: Breast Cancer; Ovarian Cancer; Liposarcoma; Non-small Cell Lung Cancer (NSCLC); Endometrial; Solid Tumors Interventions: Drug: PF-07224826; Combination Product: Fulvestrant Sponsor: Pfizer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | Endometrial Cancer | Liposarcoma | Non-Small Cell Lung Cancer | Pfizer | Research | Study